
Overview
Dr. Uppal is a board-certified Gynecologic Oncologist and Division Chief for the Gynecology Oncology service at the University of Michigan. He is also the Director of Gynecologic Oncology Initiatives at the Michigan Oncology Quality Consortium (MOQC) - a statewide quality improvement network. Dr. Uppal received his medical degree from the All India Institute of Medical Sciences (AIIMS) in New Delhi, India. He completed his Obstetrics and Gynecology residency at Temple University Hospital in Philadelphia and a fellowship in Gynecology Oncology at the University of Wisconsin in Madison, Wisconsin. He joined the faculty of the University of Michigan in 2014. Dr. Uppal also holds a Master in Business Administration (MBA) from the University of the Michigan Stephen M. Ross School of Business.Dr. Uppal has been in clinical practice for over ten years and is involved in many Quality Improvement Projects in the Division of Gynecologic Oncology, nationally and across Michigan. Widely acknowledged as a thought leader in Gynecology Oncology and quality-of-care, he has authored over 75 peer-reviewed manuscripts and instituted changes in the health system to improve outcomes after surgery, reduce the cost of care and implemented patient-centered care delivery systems.
Dr. Uppal is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy.
Dr. Uppal is board certified in Gynecologic Oncology and Obstetrics & Gynecology. He is actively involved in clinical research, co-authoring 103 peer reviewed articles and participating in 3 clinical trials. Dr. Uppal is currently accepting new patients.
Specialties
Licenses
Board Certifications
Fellowships
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- OTHER MEDICAID
- STATE MEDICAID
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- HMO
- POS
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER COMMERCIAL
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
1500 E Medical Center Dr, Floor 1, Ann Arbor, MI 48109
7500 Challis Rd, Entrance1, Level 1, Brighton, MI 48116
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
3 Clinical Trials
Rogel Cancer Center
Rashmi Chugh is an Oncologist and a Hematologist practicing medicine in Ann Arbor, Michigan. Dr. Chugh is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Desmoid Tumor, and Ewing Sarcoma. Dr. Chugh is currently accepting new patients.
Rogel Cancer Center
Scott Schuetze is an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Schuetze is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Liposarcoma, Adult Soft Tissue Sarcoma, Angiosarcoma, and Myxoid Liposarcoma. Dr. Schuetze is currently accepting new patients.
Rogel Cancer Center
Dr. Francis Worden received his medical degree from the Indiana University School of Medicine in 1993. Prior to attending medical school, he worked as a registered pharmacist at a large community hospital in Indianapolis. In 1997, Dr. Worden completed a combined residency in internal medicine and pediatrics at the Detroit Medical Center and finished a medical oncology/hematology fellowship at the University of Michigan. In July 2000, Dr. Worden joined the faculty at the University of Michigan Rogel Cancer Center, where he is currently working as a clinical investigator with both the multidisciplinary head and neck oncology team and the multidisciplinary lung cancer team. Dr. Worden's research interests include organ preservation in head and neck cancer and endocrine oncology. He is the Nancy Wigginton Oncology Research Professor of Thyroid Cancer. Avid competitive swimmer ; cyclist and runner. Dr. Worden is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Thyroid Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC). Dr. Worden is board certified in Medical Oncology. Dr. Worden is currently accepting new patients.
Rogel Cancer Center
Dr. Vaishampayan is the Director of the Phase I program at the Rogel Cancer Center, University of Michigan, Ann Arbor MI. Dr. Vaishampayan is a Professor of Internal Medicine and her research is primarily in translational drug development and early phase clinical trials in cancer with a focus on genitourinary malignancies. She has initiated, obtained funding for, and conducted and published many investigator initiated trials with embedded biomarkers and established multidisciplinary collaboration. She has served as site PI of the UO-1 Early Therapeutics Research Grant at Wayne State University. She was also the chair of the solid tumor division of oncology at WSU. She has completed formal leadership traning course and is Fellow of the Advisory Board (FAB). She is the appointed chair of the Advanced Renal committee of SWOG and a member of the Renal task force of the NCI. She is a board member of the Michigan Society of Hematology/Oncology (MSHO) and organizes annual board review course. Additionally, she has served as track leader for the ASCO education committee GU non prostate (Renal and bladder cancer) track. Dr. Vaishampayan attended Wayne State University for her residency and fellowship completion and attended medical school at Byramjee Jeejeebhoy in Pune, India and completed a higher secondary certificate in the field of science at Fergusson College in Pune, India.In her free time, Dr. Vaishampayan enjoys reading, dance, music and travel. Travel, reading (mysteries preferred), follows football. Dr. Vaishampayan is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Orchiectomy. Dr. Vaishampayan is board certified in Medical Oncology. Dr. Vaishampayan is currently accepting new patients.
Rogel Cancer Center
The T-cell lymphomas are a heterogeneous and poorly understood group of non-Hodgkin’s lymphomas. The most common T-cell lymphoma in the United States includes a heterogeneous mix of lymphomas that lack distinguishing characteristics and, until recently, remained clinically and molecularly “unspecified”. Improved understanding of T-cell lymphoma pathogenesis and the development of novel therapeutic strategies will be needed to address this challenge and improve outcomes for patients afflicted with these aggressive lymphomas. My group made the landmark discovery that the most common T-cell lymphoma in North America is comprised of two molecularly and clinically distinct subsets. This finding has significant implications for the classification and treatment of these lymphomas. We have also demonstrated that malignant T cells remain dependent upon antigen-presenting cells within the tumor microenvironment and are developing novel therapeutic strategies targeting these cells. Many fundamental questions, including the “cell of origin”, the role of antigen-, costimulatory-, and cytokine-receptor signaling, and the contribution of myeloid-derived antigen-presenting cells in disease pathogenesis remain obscure. My laboratory uses complementary mouse models and primary T-cell lymphoma specimens (in ex vivo and patient-derived xenograft studies) to address these fundamental and clinically relevant questions. We are poised to clinically translate our laboratory-based findings into novel therapeutic strategies that we hope will improve outcomes for patients afflicted with these aggressive lymphomas. I enjoy working with a multidisciplinary team of enthusiastic collaborators who share this common goal. Dr. Wilcox is highly rated in 24 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Wilcox is board certified in Hematology, Internal Medicine, and Medical Oncology. Dr. Wilcox is currently accepting new patients.
Rogel Cancer Center
Dr. Kalemkerian completed his medical education and training at Northwestern University and Johns Hopkins Oncology Center. From 1993-1999, he was a physician-scientist at Wayne State University/Karmanos Cancer Institute in Detroit. Since 1999, he has been on faculty in the Division of Hematology/Oncology at the University of Michigan, where he currently serves as the Associate Division Chief for Faculty Development and Education and the Associate Director of the Hem/Onc Fellowship Program. In addition to his work at UM, Dr. Kalemkerian has served on and led numerous grant review sections, editorial boards, and committees of national and international professional societies. He is a former chair of the NCCN Small Cell Lung Cancer Guideline Panel and the ASCO Scientific Program Committee’s Metastatic NSCLC and Professional Development and Education Tracks. Dr. Kalemkerian’s clinical interest is the care of people with lung cancer, thymic tumors, and mesothelioma, and his academic research interest is clinical and translational trials for thoracic cancers. His honors include the receipt of the American Society of Clinical Oncology’s (ASCO) Excellence in Teaching Award, the University of Michigan Outstanding Clinician Award, and Fellow of ASCO recognition. He has given over 230 invited lectures, authored more than 200 research articles, reviews, commentaries and book chapters, and edited two books on lung cancer. Dr. Kalemkerian is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Kalemkerian is board certified in Internal Medicine and Medical Oncology. Dr. Kalemkerian is currently accepting new patients.
Frequently Asked Questions about Dr. Shitanshu R. Uppal
How do I make an appointment with Dr. Shitanshu R. Uppal?
You can book an appointment with Dr. Shitanshu R. Uppal by calling their office at 734-647-8902. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Shitanshu R. Uppal a top-rated expert for Hysterectomy?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Shitanshu R. Uppal is classified as an Elite expert for Hysterectomy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Shitanshu R. Uppal specialize in?
While Dr. Shitanshu R. Uppal is a Oncology, they have specific expertise in Hysterectomy, Ovarian Cancer, and Endometrial Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.
Does Dr. Shitanshu R. Uppal participate in research or clinical trials?
Yes. Dr. Shitanshu R. Uppal has published 102 articles and abstracts on conditions like Hysterectomy. You can view a list of Dr. Shitanshu R. Uppal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. Shitanshu R. Uppal accept my insurance?
Dr. Shitanshu R. Uppal accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 734-647-8902 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- HysterectomyDr. Uppal isElite. Learn about Hysterectomy.
- Ovarian CancerDr. Uppal isElite. Learn about Ovarian Cancer.
- Distinguished
- Cervical CancerDr. Uppal isDistinguished. Learn about Cervical Cancer.
- Endometrial CancerDr. Uppal isDistinguished. Learn about Endometrial Cancer.
- Endometrial Stromal SarcomaDr. Uppal isDistinguished. Learn about Endometrial Stromal Sarcoma.
- Malignant Mixed Mullerian TumorDr. Uppal isDistinguished. Learn about Malignant Mixed Mullerian Tumor.
- Neuroendocrine Carcinoma of the CervixDr. Uppal isDistinguished. Learn about Neuroendocrine Carcinoma of the Cervix.
- Ovarian CarcinosarcomaDr. Uppal isDistinguished. Learn about Ovarian Carcinosarcoma.
- Sertoli-Leydig Cell TumorDr. Uppal isDistinguished. Learn about Sertoli-Leydig Cell Tumor.
- Testicular Yolk Sac TumorDr. Uppal isDistinguished. Learn about Testicular Yolk Sac Tumor.
- Virilizing Ovarian TumorDr. Uppal isDistinguished. Learn about Virilizing Ovarian Tumor.
- Vulvar CancerDr. Uppal isDistinguished. Learn about Vulvar Cancer.
- Advanced
- Adult Soft Tissue SarcomaDr. Uppal isAdvanced. Learn about Adult Soft Tissue Sarcoma.
- BRCA Positive Breast CancerDr. Uppal isAdvanced. Learn about BRCA Positive Breast Cancer.
- Desmoplastic Small Round Cell Tumor
- DICER1 SyndromeDr. Uppal isAdvanced. Learn about DICER1 Syndrome.
- Eccrine PorocarcinomaDr. Uppal isAdvanced. Learn about Eccrine Porocarcinoma.
- Gestational Trophoblastic Disease
- HER2 Negative Breast CancerDr. Uppal isAdvanced. Learn about HER2 Negative Breast Cancer.
- Hydatidiform MoleDr. Uppal isAdvanced. Learn about Hydatidiform Mole.
- Li-Fraumeni SyndromeDr. Uppal isAdvanced. Learn about Li-Fraumeni Syndrome.
- Lump in the AbdomenDr. Uppal isAdvanced. Learn about Lump in the Abdomen.
- Pelvic Congestion SyndromeDr. Uppal isAdvanced. Learn about Pelvic Congestion Syndrome.
- Pseudomyxoma PeritoneiDr. Uppal isAdvanced. Learn about Pseudomyxoma Peritonei.
- Vaginal CancerDr. Uppal isAdvanced. Learn about Vaginal Cancer.
- Experienced
- AgranulocytosisDr. Uppal isExperienced. Learn about Agranulocytosis.
- Alveolar Soft Part SarcomaDr. Uppal isExperienced. Learn about Alveolar Soft Part Sarcoma.
- AngiomyomaDr. Uppal isExperienced. Learn about Angiomyoma.
- Appendix CancerDr. Uppal isExperienced. Learn about Appendix Cancer.
- Bladder ReconstructionDr. Uppal isExperienced. Learn about Bladder Reconstruction.
- Bone TumorDr. Uppal isExperienced. Learn about Bone Tumor.
- Chronic Familial NeutropeniaDr. Uppal isExperienced. Learn about Chronic Familial Neutropenia.
- EndometriosisDr. Uppal isExperienced. Learn about Endometriosis.
- EndometritisDr. Uppal isExperienced. Learn about Endometritis.
- EndoscopyDr. Uppal isExperienced. Learn about Endoscopy.
- Epithelioid SarcomaDr. Uppal isExperienced. Learn about Epithelioid Sarcoma.
- Familial Colorectal CancerDr. Uppal isExperienced. Learn about Familial Colorectal Cancer.
- FasciotomyDr. Uppal isExperienced. Learn about Fasciotomy.
- FibrosarcomaDr. Uppal isExperienced. Learn about Fibrosarcoma.
- GanglioneuroblastomaDr. Uppal isExperienced. Learn about Ganglioneuroblastoma.
- GanglioneuromaDr. Uppal isExperienced. Learn about Ganglioneuroma.
- HemangiopericytomaDr. Uppal isExperienced. Learn about Hemangiopericytoma.
- Hernia SurgeryDr. Uppal isExperienced. Learn about Hernia Surgery.
- HydroceleDr. Uppal isExperienced. Learn about Hydrocele.
- Intestinal LeiomyomaDr. Uppal isExperienced. Learn about Intestinal Leiomyoma.
- LiposarcomaDr. Uppal isExperienced. Learn about Liposarcoma.
- MelanomaDr. Uppal isExperienced. Learn about Melanoma.
- MesenchymomaDr. Uppal isExperienced. Learn about Mesenchymoma.
- Myxoid LiposarcomaDr. Uppal isExperienced. Learn about Myxoid Liposarcoma.
- Neonatal Ovarian CystDr. Uppal isExperienced. Learn about Neonatal Ovarian Cyst.
- Neuroendocrine TumorDr. Uppal isExperienced. Learn about Neuroendocrine Tumor.
- OophorectomyDr. Uppal isExperienced. Learn about Oophorectomy.
- Ovarian CystsDr. Uppal isExperienced. Learn about Ovarian Cysts.
- Pelvic Inflammatory DiseaseDr. Uppal isExperienced. Learn about Pelvic Inflammatory Disease.
- Placenta PreviaDr. Uppal isExperienced. Learn about Placenta Previa.
- Rhabdoid TumorDr. Uppal isExperienced. Learn about Rhabdoid Tumor.
- Rhabdoid Tumor Predisposition Syndrome
- RhabdomyosarcomaDr. Uppal isExperienced. Learn about Rhabdomyosarcoma.
- Rhabdomyosarcoma EmbryonalDr. Uppal isExperienced. Learn about Rhabdomyosarcoma Embryonal.
- Salpingo-OophorectomyDr. Uppal isExperienced. Learn about Salpingo-Oophorectomy.
- Severe Congenital NeutropeniaDr. Uppal isExperienced. Learn about Severe Congenital Neutropenia.
- Synovial SarcomaDr. Uppal isExperienced. Learn about Synovial Sarcoma.
- Undifferentiated Pleomorphic SarcomaDr. Uppal isExperienced. Learn about Undifferentiated Pleomorphic Sarcoma.
- Uterine FibroidsDr. Uppal isExperienced. Learn about Uterine Fibroids.
- Venous Thromboembolism (VTE)Dr. Uppal isExperienced. Learn about Venous Thromboembolism (VTE).





